Effectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-19.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstituto de Investigación Sanitaria Aragón

About this trial

This Randomized Controlled Trial (RCT) aims to assess the effectiveness and acceptability of the Unified Protocol (UP) in an online group format for the treatment of emotional disorders in adults. Participants will be 90 adults (45 in the control group and 45 in the experimental group) with diagnosis of long COVID and comorbid emotional disorders. Participants will be recruited at Hospital Royo Villanova from Zaragoza, Spain.

In this study it will be explored whether the changes obtained after the intervention in emotional disorders and cognitive complaints are maintained over 12 months. Additionally, levels of chronic stress will be longitudinally evaluated in the experimental group through accumulated cortisol levels in hair, before and after the application of the UP.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Residing in Autonomous Community of Aragon (Spain).

Being at least 18 years old.

Understanding of Spanish.

Being diagnosed with long COVID-19: documented SARS-CoV-2 infection and persistence of symptoms beyond 12 weeks after the acute infection.

Disqualifiers

Pre-existing emotional symptoms prior to the acute SARS-CoV-2 infection.

Actually receiving psychological treatment.

Having a diagnosis of severe mental disorder (e.g., personality disorder, bipolar disorder, etc.).

Active suicidal ideation at the time of the assessment.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders

    Behavioral

    This transdiagnostic psychological intervention is focused on training emotion regulation skills. This program is composed by 8 modules (core modules are 3 to 7). In this study we will use a group online format (videocalls). Each sessin will last 2 hours. The contents of the UP will be distributed in 12 online sessions as follows: * Module 1 (session 1): Setting goals and maintaining motivation. * Module 2 (sessions 2 and 3): Understanding your emotions. * Module 3 (sessions 4 and 5): Mindful Emotions Awareness. * Module 4 (sessions 6 and 7): Flexible thinking. * Module 5 (session 8): Emotional baheviors. * Module 6 (session 9): Facing physical sensations. * Module 7 (sessions 10 and 11): Emotionl exposures. * Module 8 (Session 12): Relapse prevention.

  • Treatment as Usual (TAU)

    Other intervention

    This intervention will act as a control condition. During the waiting period (12 weeks) participants assigned to this condition will continue receiving Treatment As Usual at the Royo Villanova Hospital. It consists of regular contact with doctors to monitor the physical symptomsof long COVID-19. After the 12 weeks, participants in this conditions will join the experimental group and they will receive the psychological intervention following the same procedure described for the experimental condition.

Treatment groups

90 Participants
are divided into 2 treatment groups
Group A: Unified Protocol Psychological InterventionExperimental treatment 1 intervention
Group B: Control Group-Waiting listOther 1 intervention

Trial outcomes

Primary outcomes

1

General Depression Severity and Interference Scale (ODSIS; Bentley et al., 2014. Validated in Spanish by Osma et al., 2019)

It assesses the frequency, intensity, severity and interference of depressive symptomatology through 5 items. total scores range from 0 to 20 points, higher scores indicating more severe depressive symptoms.

Time frame
Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
2

General Severity and Interference Scale for Anxiety (OASIS; Norman et al., 2006. Validated in Spanish by Osma et al., 2019)

It consiste of 5 items that assess the frequency, intensity, severity and interference of anxious symptomatology. Total scores range from 0 to 20 points, higher scores represent more severe anxiety symptoms.

Time frame
Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)

Secondary outcomes

1

Memory Failures of Everyday, MFE (Sunderland et al., 1983; Montejo et al., 2014)

It assesses the frequency of forgetfulness and memory lapses in daily life. Errors include forgetting names, misplacing objects, difficulties in planning, or lapses in attention.

Time frame
Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
2

Multidimensional Inventory for Emotional Disorders (MEDI; Rosellini and Brown, 2019. Validated in Spanish by Osma et al., 2023)

It is composed by 49 items that evaluates the transdiagnostic profile of Emotional Disorders, which is composed of nine dimensions: neurotic temperament, positive temperament, depressed mood, somatic anxiety, arousal activation, social anxiety, intrusive cognitions, traumatic re-experiencing, and avoidance.

Time frame
Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
3

Emotional Regulation Difficulties Scale (DERS; Gratz and Roemer, 2004. Validated in Spanish by Hervás & Jódar, 2008)

Evaluation through 36 items of difficulties in emotional regulation by means of 5 subscales: lack of control, rejection, interference, inattention and emotional confusion. Higher scores indicate greater difficulties in emotion regulation.

Time frame
Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)
4

EuroQol (Brooks, 1996. Validated in Spanish by Badia et al., 1999)

It is composd by 5 items assessing self-perceived health status. Higher scores indicate better quality of life.

Time frame
Before the treatment, after the treatment, at three points follow up (3, 6 and 12 months after the intervention ended)

Other outcomes

1

Structured interview for anxiety disorders and related disorders, according to the DSM-5 (ADIS-5; Brown & Barlow, 2014)

Diagnostic interview to determine the clinical diagnosis of emotional disorder (ED). The following diagnoses according to the DSM-V are included within the category of emotional disorder: major depressive disorder, dysthymic disorder, panic disorder, agoraphobia, obsessive-compulsive disorder, generalized anxiety disorder, post-traumatic stress disorder, social anxiety disorder, hypochondria, and adjustment disorders. Patients with anxiety disorders not otherwise specified and those with depressive disorders not otherwise specified will also be included in the study.

Time frame
Before the treatment is administered to determine inclusion criteria (approximately 2 weeks before the interventions starts)
2

Sociodemographic information

Ad hoc questionnaire to assess: Sex, age, place of residence, marital status, employment status, lifestyle habits (smoking, alcohol, physical activity, diet), vaccination against SARS-CoV-2 information.

Time frame
Before the treatment is administered to characterize the sample (approximately 2 weeks before the interventions starts).
3

Long COVID-19 pre-assessment questionnaire

This questionnaire is designed to assess the symptoms and impact of long COVID-19 symptoms on patients' daily lives. It evaluates information about physical and cognitive function as well as levels of fatigue and COVID-19 infection history.

Time frame
Before the treatment is administered to characterize the sample (approximately 2 weeks before the interventions starts).

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Instituto de Investigación Sanitaria Aragón

Lead sponsor

Universidad de Zaragoza

Sponsor institution

Hospital Royo Villanova de Zaragoza

Collaborator